Abstract: For approximately 30 years, statins have been effectively used to control cholesterol, thereby reducing the morbidity and mortality associated with cardiovascular disease. Evidence-based recommendations regarding how these drugs are dosed and used have changed significantly through the years. There are seven statins approved for use in the United States, and although the mechanism of action pertaining to cholesterol reduction is the same for all statins, each has its own specific pharmacologic profile. One unique aspect of statin dosing is understanding the potential drug interactions associated with statin use; interactions can occur with all statins, but the mechanism and type of interaction can vary significantly among drugs. These interactions can result in significant elevations in statin blood concentrations, thereby increasing the risk of the adverse effects of statins, the most significant of which is muscle toxicity. Practitioners who care for patients receiving statins should understand the pharmacologic differences among these drugs, as well as the varied drug interaction potential that all statins possess.
I
n 1987, lovastatin became the first 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitor (better known as "statins") to be approved by the US Food and Drug Administration (FDA) for the treatment of hypercholesterolemia. 1 Several statins are now sold in the United States. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] (Supplemental Table  1 , http://links.lww.com/SMJ/A77) The early, first-generation statins include lovastatin, pravastatin, and fluvastatin; simvastatin and atorvastatin are classified as second-generation statins, and the remaining statins (rosuvastatin and pitavastatin) are classified as third-generation statins. 1, 2 The second-and third-generation statins, especially atorvastatin and rosuvastatin, are predominantly prescribed because of their effectiveness at reducing low-density lipoprotein-cholesterol (LDL-C) at a much greater rate than other statins. 1, 2 Because cardiovascular disease is a leading cause of morbidity and mortality throughout the world, statin use is common. Reducing LDL-C and triglycerides while increasing high-density lipoprotein-cholesterol (HDL-C) remains an important goal in the effort to reduce the incidence of myocardial infarctions (MIs), strokes, peripheral vascular diseases, and other problems. Hypercholesterolemia is linked to other common diseases such as diabetes mellitus, hypertension, the metabolic syndrome, and obesity. [1] [2] [3] Millions of patients around the world are receiving statin therapy. Once statin therapy is initiated, in general it is continued for the rest of a patient's life. As patients age and more drugs are added to the patient's pharmacotherapy regimen, the risk for statin-drug interactions increases proportionately. Understanding the pharmacology of statins and the types of potential drug interactions that occur with statins will allow the practitioner to monitor patients prospectively for possible adverse effects that can occur as result of drug interactions. This article reviews the pharmacology of statins, including the most common adverse reactions for which practitioners must monitor. In addition, the types and mechanisms of possible statin-drug interactions are discussed, including how these interactions should be assessed and monitored.
Basic Statin Pharmacology
The primary lipid-lowering effects of statins derive from their ability to inhibit HMG-CoA reductase, which is responsible for converting HMG-CoA to mevalonate, an early step in LDL-C synthesis. 4, 5 This action takes place in the liver hepatocytes. This mechanism of action induces a compensatory increase in LDL receptors, which bind and remove circulating LDL-C. 5 Statins also may cause a mild reduction in very-low-density lipoproteins and triglycerides, and they may induce a slight increase in HDL-C. [4] [5] [6] [7] The pharmacokinetic profile of each statin is illustrated in Supplemental Table 1 , http://links.lww.com/SMJ/A77. The statins vary significantly in their oral absorption, half-life, lipophilicity, and metabolic pathway in the liver. [4] [5] [6] [7] [8] The more lipophilic statins (eg, simvastatin, atorvastatin) appear to enter the hepatocytes via passive diffusion, whereas the hydrophilic statins (eg, pravastatin, rosuvastatin) must rely on carrier proteins for entry into the hepatocytes. Lipophilic statins rely heavily on the cytochrome P450 (CYP450) mixed-function oxidase system for 
Notes
Combining the above drug classes/drugs with lovastatin, simvastatin, or atorvastatin will cause increased statin blood concentrations via CYP450 interactions as well as interactions via the transporter mechanism.
Combining the above drug classes/drugs with fluvastatin, pravastatin, rosuvastatin, or pitavastatin will result in higher statin blood concentrations via an interaction with transporter mechanisms.
In these situations, statin doses should be reduced significantly. The statin dose may be titrated up slowly, but patient tolerability must be monitored closely. Take-home points
The number of patients prescribed HMG-CoA reductase inhibitors (statins) in the US is significant. Healthcare providers must understand the pharmacology of these drugs to maximize their benefits and minimize their risks As illustrated in Supplemental Table 1 , the pharmacology of specific statins can vary widely. Using this information should aid practitioners in prescribing the appropriate statins for their patients. Practitioners also should be aware of the statin utilization guidelines established by the ACC and the AHA. These guidelines dictate how statins should be used in primary and secondary prevention of thromboembolic disease. Supplemental Table 2 lists the 4 groups that benefit from statin therapy based upon the ACC-AHA guidelines. Healthcare providers must understand both the risks and benefits of statin therapy when using these drugs to treat their patients. The primary risk of statin therapy is muscle toxicity, which may include myalgias, myositis, and rhabdomyolysis. Dosing statins appropriately in specific patients is key to preventing toxicity with statins.
The risk of significant toxicity with statins caused by drug-drug interactions can happen to any patient. All patients prescribed a statin drug must be instructed on the risk of muscle pain and myalgias. It must be emphasized to all patients on statin therapy that if muscle pain occurs at any time during statin therapy, they should contact their healthcare provider.
Patients who are at a much greater risk for statin toxicity caused by drug-drug interaction must be identified. These patients should be monitored closely. Patients/ caregivers must be educated about the risk of muscle pain and myalgias. Any patients who have experienced drug-drug interactions may have a genetic predisposition to drug-drug interactions. These patients may have an increased risk for statin-drug interactions.
Practitioners should be aware of the different types of drug interactions that could lead to statin toxicity: CYP450 interactions; statin interactions via transporters (OATP1B1, OATP1B3, Pgp-1).
Practitioners should be aware of the high-risk drugs listed above that when administered with statins could lead to toxic statin blood concentrations. Appropriate guidelines for limiting statin toxicity should be followed.
If possible, avoid drugs that have both CYP450 and transporter (OATP1B1, OATP1B3, Pgp-1) interactions with statins.
ACC, American College of Cardiology; AHA, American Heart Association; CYP450, cytochrome P450; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; OATP, organic anion-transporting polypeptide; OTC, over the counter; Pgp-1, permeability glycoprotein-1.
Adapted from references 37-40. metabolism, whereas hydrophilic statins rely on alternative routes for metabolism and clearance. Pravastatin is degraded partially in the stomach and metabolized within the cytosol of the hepatocytes; rosuvastatin is degraded in the stomach and undergoes minimal metabolism via the CYP450 system. Understanding the specific metabolic pathway for each statin can help predict potential drug interactions with the statins.
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Statin Utilization
As a class, statins have several FDA-approved indications, although not all statins are approved for the same disorders. Some general indications include the following:
• Primary hypercholesterolemia and mixed dyslipidemia • Primary prevention: statins can reduce the risk of a cardiovascular event (eg, MI, stroke, death) in patients at high risk of atherosclerotic cardiovascular disease. Statins also can reduce the risk of a cardiovascular event/symptoms (eg, angina, MI, stroke) in patients without clinically evident coronary heart disease (CHD). In addition, statins can reduce the incidence of MI and stroke in patients with type 2 diabetes mellitus, with or without clinically evident CHD.
• Secondary prevention: statins can decrease the incidence of a cardiovascular event (eg, angina, MI, stroke, hospitalization) in patients with clinically evident CHD.
The impact of statins in reducing morbidity and mortality from cardiovascular diseases has been significant. For many years the dosing strategy for all statins was to prescribe a daily dose that could reduce LDL-C sufficiently to achieve a desired target LDL-C (eg, LDL-C <100 mg/dL). 11 Statin drug selection and dose were based largely on how well a particular drug and dose could achieve the target LDL-C. In 2013, this statin utilization strategy was altered significantly based on new guidelines established by the American College of Cardiology and the American Heart Association and developed in conjunction with the National Heart, Lung, and Blood Institute. 12, 13 These new evidence-based guidelines for cholesterol management are not based on specific target LDL-C or HDL-C levels. Instead, these new guidelines identify four main patient groups in whom primary and secondary prevention has been shown to be essential (Supplemental Table 2 , http://links.lww.com/SMJ/ A77). The guidelines recommend a specific "intensity" of statin therapy that is designed to achieve relative reductions in LDL-C so as to prevent atherosclerotic cardiovascular disease in that particular group. A patient meeting specific qualifications for statin therapy will be treated with high-, moderate-, or low-intensity statin therapy. Because cardiovascular disease is a major cause of morbidity and mortality in the United States, many patients meet the criteria for statin therapy.
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Monitoring Statin Therapy
Before statins are initiated, some laboratory monitoring is recommended. A basic lipid panel should be obtained (LDL, HDL, total cholesterol, triglycerides). Although current recommendations do not aim for a specific LDL/HDL goal, it is important that patients are assessed for excessive hyperlipidemia as well as hypertriglyceridemia. Baseline liver function tests ([LFTs] alanine transaminase, aspartate transaminase, alkaline phosphatase) also should be obtained before statins are prescribed. Practitioners also should consider ordering a baseline creatine kinase (CK) because some patients may experience muscle pain or myositis while taking statins. Other routine monitoring may include baseline kidney function, baseline thyroid function tests, or an assessment for diabetes mellitus (fasting glucose, glycosylated hemoglobin).
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Toxicity of Statins
Most patients tolerate statin therapy well. After many years of statin therapy, the adverse effect profile for these drugs has evolved somewhat as information has been collected regarding statin use in patients of all ages, sexes, and ethnicities.
1,2 Common adverse effects of statins include mild gastrointestinal complaints such as stomach upset, diarrhea, or constipation. 1, 4 Mild headache and muscle aches also have been noted as common adverse reactions.
1,2,7 Although infrequent, more severe adverse effects with statins include hepatotoxicity and intense muscle pain that results from statin-induced muscle damage. These adverse effects are uncommon at therapeutic doses; however, with statin toxicity caused by excessive dosing or an elevation of statin blood concentrations induced by specific statin-drug interactions, these severe adverse drug reactions are more prevalent and can become problematic.
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Hepatotoxicity
Initially, hepatotoxicity was a major concern with statins because their primary mechanism of action occurs in the liver and many patients take these drugs for their lifespan. Reported hepatic adverse reactions include asymptomatic elevation of serum transaminases (LFTs), hepatitis, cholestasis, and acute liver failure. All of these effects are dose related. [21] [22] [23] FDA recommendations for monitoring LFTs in patients taking statins have changed since the first-generation statins were introduced. Various studies and case reports have demonstrated that hepatotoxicity with statins is rare. As such, in 2012 the FDA revised the labeling requirements for all statins. It is no longer required that periodic or routine LFT monitoring be conducted in patients receiving statins. The FDA recommends that baseline LFTs be obtained before statin therapy is initiated and as clinically indicated thereafter. Potential statin-drug interactions, which may induce statin toxicity, may potentiate the need for more frequent monitoring of a patient's hepatic function.
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Muscle Effects and Myopathy
The most notable adverse effect of statins is muscle toxicity. The incidence of muscle pain and myopathy is much more prevalent with elevated statin blood concentrations. Muscle toxicity can range from mild muscle aches and pains to severe myopathy and myositis, which can lead to a significant elevation of plasma CK. Myopathy and myositis can cause severe pain, tenderness, weakness, and a restriction of mobility. The adverse effects on the muscle and subsequent muscle damage can include the following:
• Myalgia: muscle pain, weakness, and soreness without elevation of CK • Myositis: inflammation of the muscle fibers; may or may not include muscle pain; does include elevation of CK • Rhabdomyolysis: muscle pain, soreness, weakness with elevation of CK level 10 times the upper limit of normal or higher. This may occur with or without evidence of renal dysfunction.
For patients receiving chronic statin therapy, mild muscle pain is not unusual, especially if it follows exercise or a strenuous activity. If this pain is severe or persistent or if it occurs following medication or dosage changes, then patients should be encouraged to contact their healthcare provider. In most cases, statin-induced myopathy is self-limiting and will subside when the statin is discontinued or the dose is reduced. Some patients report permanent myopathy even when the drug is stopped, although this is extremely rare. Most practitioners recommend discontinuing statin therapy and restarting at a lower dose once the muscle pain subsides. [28] [29] [30] [31] Severe muscle damage can lead to rhabdomyolysis, which is characterized by severe pain and an elevation of CK at 5 to 10 times above the upper limit of normal. If left untreated and if CK levels continue to rise, then rhabdomyolysis can lead to severe kidney damage that may be irreversible. Statins are notable for causing drug-induced rhabdomyolysis, although various drugs/drug classes also have been implicated. Rhabdomyolysis can be treated effectively by discontinuing the offending agent and treating the patient with appropriate intravenous hydration. 28 The risk of rhabdomyolysis may increase if a patient, who is receiving statins, also incurs muscle damage from another source (eg, strenuous exercise, trauma, cocaine use). To prevent statin-induced muscle injury, CK levels must be appropriately monitored, especially in high-risk patients (high incidence of drug interactions or patients with a history of muscle injury). It also is imperative that all patients taking statins be appropriately educated about the risk of statin-induced muscle injury. [31] [32] [33] [34] The precise mechanism of statin-induced muscle toxicity is unclear. It is more common with toxic doses or drug interactions that result in elevated statin blood concentrations. Statins that are more chemically hydrophilic (eg, fluvastatin, pravastatin) may cause less myopathy than the more lipophilic statins (eg, simvastatin), although this is not always true. 28, [31] [32] [33] There is some evidence that statins can cause changes in mitochondrial oxidative metabolism within the muscle, which can impair the ability of the muscle to produce the energy it needs to function. A statininduced reduction of coenzyme Q10 may contribute to this toxic effect, although this also remains unclear. 35, 36 Clinically Significant Drug Interactions Clinically significant drug interactions can occur with all statins. For the most part statins do not interfere with the absorption, metabolism, or clearance of other drugs. There are, however, several drugs that can alter the absorption, metabolism, or clearance of statins and this can result in clinically significant elevations of statin blood concentrations that can lead to adverse effects. In adult patients of average age who have normal hepatic/renal function and who are taking few concurrent medications, the risk of a significant statin-drug interaction is minimal. Statin-drug interactions tend to be more prominent in elderly patients, patients taking several other concurrent medications, patients who are severely ill, or patients who have compromised renal or hepatic problems. In such patients, statin-drug interactions have been shown to be clinically significant and may result in an increase in patient morbidity. [37] [38] [39] Statin-Drug Interactions Mediated by the CYP450 System
As mentioned earlier most of the lipophilic statins are metabolized extensively in the liver via the CYP450 mixed-function oxidase system (the exceptions being pravastatin and rosuvastatin). The precise metabolic pathway for the available statins is listed in Supplemental Table 1 , http://links.lww.com/SMJ/A77. Various drugs can act as either inducers or inhibitors for each CYP450 pathway (eg, CYP3A4, CYP2C9, CYP2C19). For the most part statins do not affect the metabolism of other drugs but rather act as substrates for various inducers or inhibitors. Supplemental Table 3 , http://links.lww.com/SMJ/A77 illustrates some of these CYP450 drug interactions. [37] [38] [39] The potential for a statin-drug interaction via the CYP450 system does not affect all statins equally. Simvastatin and lovastatin appear to have a much greater risk of a CYP450 drug interaction than the other statins. Atorvastatin poses a moderate risk for a CYP450 drug interaction, whereas fluvastatin, pitavastatin, rosuvastatin, and pravastatin pose the least risk of a CYP450 interaction. 38 The most notable statin-drug interactions are with inhibitors of the CYP3A4 subsystem, resulting in clinically significant elevations in statin blood concentrations. Similar interactions exist for those statins metabolized via CYP2C9. 38, 39 Inducers of statin metabolism also may cause changes in statin blood concentrations. Whether or not increasing the metabolism of some statins results in clinically significant effects is unclear. Whereas inhibition of CYP450 enzymes generally occurs relatively quickly (a few days), the induction process can take weeks before its full effect is determined. In addition, many inducers speed up their own metabolism, which would result in a diminished effect on the substrate. 38, 39 The potential CYP450 drug interactions that exist with statins are significant. The Table provides some treatment suggestions for when statins are combined with certain highrisk inhibitors of the CYP450 system.
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Statin Interactions Via Transporters
Statins, as well as many other drugs, require specific transporter proteins to move them across membranes to gain access to the cellular structure of various organs (eg, liver, kidneys). For statins specifically, transporter proteins, labeled as organic anion-transporting polypeptide-1B1 (OATP1B1) and OATP1B3, are responsible for transporting the statin into the liver hepatocyte. 38, 40, 41 As with the CYP450 system, various drugs can inhibit OATP1B1 and OATP1B3, causing statin concentrations in the blood to increase. Supplemental Table 3 , http://links.lww. com/SMJ/A77 illustrates the various drugs that can inhibit these transporter proteins. As mentioned previously, the hydrophilic statins tend to rely to a greater extent than the lipophilic statins on these carrier proteins to transport the statin across the membrane and into the hepatocyte. It appears that the metabolism of all statins (to some extent) can be influenced via the inhibition of OATP1B1, causing a clinically significant elevation of statin blood concentrations. 38, 40, 41 Statin transport also may be affected by another transporter protein type, known as permeability glycoprotein-1 (or Pgp-1, Pgp). This protein is located on the cell membrane of most cells and is responsible for pumping foreign substances (eg, drugs) out of cells. Pgp-1 works as an efflux pump and, similar to OATP1B1 and OATP1B3, can be "turned off " or "turned on" by various substances. The Pgp-1 protein, located in the gut lumen of the small intestine, can influence statin bioavailability such that, if Pgp-1 is inhibited, more statin reaches the systemic circulation because it is not being pumped out of the gut lumen into the gastrointestinal tract for elimination. As with the CYP450 system, some statins are more susceptible than others when the Pgp-1 protein is inhibited by other medications. Supplemental Table 3 , http://links.lww.com/SMJ/A77, lists the statins that may be affected by this transporter, as well as the drugs that can inhibit or induce this protein. [38] [39] [40] 42 Unfortunately, there is no way to quantify or predict the precise effect that these various statin-drug interactions will have on a patient. Patients who have an increased risk of developing a clinically significant statin-drug interaction must be monitored carefully (Table) . 38, 39 Practitioner Response to Statin-Drug Interactions
There are certain high-risk drug classes/drugs for which the statin interaction risk is not only probable but clinical studies have demonstrated a high risk of morbidity. These interactions generally cause statin blood concentrations to increase significantly, making the patient more susceptible to statin toxicity. These drug classes/drugs may have a consistent and intense effect on one interaction type (ie, only the CYP450 system) or the drug classes/drugs may cause more than one type of interaction. The Table lists some of the high-risk drug classes/drugs that when combined with a statin will predictably cause high statin concentrations, which may lead to toxicity. [37] [38] [39] [40] There also are patients who are genetically predisposed to statin-drug interactions. A patient's pharmacogenetic profile may determine how a specific statin is metabolized in a patient and how other drugs affect this metabolic process. Some patients possess genetic polymorphisms that make them more susceptible to CYP450 interactions and interactions caused by transporter physiology. Eventually, as the effectiveness of general pharmacogenetic testing is proven clinically beneficial and the cost becomes more acceptable, it will be common to have a genetic profile on all patients, which will make it much easier for practitioners to predict possible drug interactions before they occur. 42 
Conclusions
The Table provides the important points from this brief review. As a drug class, statins continue to be used around the world. Understanding how to use these drugs effectively for both primary and secondary prevention of thromboembolic disease is essential. To maximize statin benefit and minimize statin toxicity, understanding the specific pharmacology for the different statins is necessary. Knowing which adverse effects of statins are most significant also is important. Statin-drug interactions can cause significant toxicity and understanding how certain drugs interact with statins will aid healthcare providers in safely prescribing these important medications. 
